```html

Yttrium‑90 Microsphere Radiation Pneumonitis

Overview

Yttrium‑90 (Y‑90) microsphere radiation pneumonitis is an inflammatory lung condition that can occur after selective internal radiation therapy (SIRT) using Y‑90‑loaded glass or resin microspheres. SIRT is a minimally invasive, liver‑directed treatment for primary liver cancer (hepatocellular carcinoma, HCC) and liver‑dominant metastases (most commonly colorectal cancer). The microspheres are injected into the hepatic artery, where they lodge in the tumor’s microvasculature and emit high‑energy beta radiation that destroys cancer cells. In a minority of patients, a portion of the microspheres migrates to the pulmonary circulation, delivering a dose of radiation to lung tissue and triggering pneumonitis.

Although rare, radiation pneumonitis after Y‑90 SIRT is clinically important because it can mimic infection, heart failure, or disease progression, and delayed recognition may lead to severe respiratory compromise.

Who it affects: Adults undergoing Y‑90 SIRT for liver cancer. The risk is higher in patients with large treatment volumes, high administered activity, or pre‑existing lung disease.

Prevalence: Published series report pulmonary radiation injury in <sup>1</sup>2‑15% of patients when lung dose is calculated >30 Gy, but clinically significant pneumonitis (grade ≥2) occurs in <1%–3% of treated individuals. The incidence varies by center, microsphere type, and adherence to lung‑dose limits.<sup>2</sup>

Symptoms

Radiation pneumonitis typically manifests 4–12 weeks after the Y‑90 procedure, though early (<2 weeks) or delayed (>6 months) presentations have been described. Symptoms can range from mild to severe.

Common symptoms

• Dry cough – persistent, non‑productive; may be mistaken for an upper‑respiratory infection.
• Dyspnea (shortness of breath) – worsens with exertion; in severe cases, occurs at rest.
• Fever – low‑grade (≤38.5 °C); high‑grade fevers should raise suspicion for infection.
• Chest tightness or pleuritic chest pain – discomfort that may increase with deep breathing.
• Fatigue – generalized weakness, often disproportionate to activity level.

Less common / severe manifestations

• Hypoxia (oxygen saturation < 90% on room air).
• Rapid, shallow breathing (tachypnea).
• Productive cough with clear or blood‑tinged sputum (rare).
• Weight loss or loss of appetite secondary to breathlessness.
• Progressive respiratory failure requiring supplemental oxygen or mechanical ventilation.

Causes and Risk Factors

Mechanism

Y‑90 microspheres are 20–30 µm in diameter. When inadvertently shunted through hepatic arteriovenous connections or because of arteriovenous malformations, they can travel to the pulmonary artery and become lodged in lung capillaries. The beta particles (maximum energy 2.28 MeV) have a tissue penetration range of ~2.5 mm, delivering a localized radiation dose that damages alveolar epithelium and pulmonary interstitium, resulting in an immune‑mediated inflammatory response.

Key risk factors

• High administered activity – exceeding manufacturer‑recommended lung dose limits (usually <30 Gy for single‑session therapy).
• Large treated liver volume – >1/3 of total liver mass increases shunt probability.
• Pre‑existing lung disease – chronic obstructive pulmonary disease (COPD), interstitial lung disease, or prior radiation therapy.
• Elevated lung shunt fraction (LSF) – measured on technetium‑99m macroaggregated albumin (Tc‑99m MAA) scan; LSF >10–15% raises concern.
• Previous hepatic arterial embolization – may alter vascular anatomy and increase shunting.
• Patient age >70 years – reduced pulmonary reserve.
• Concurrent systemic chemotherapy – especially agents that are also pneumotoxic (e.g., bleomycin, gemcitabine).

Diagnosis

Diagnosing radiation pneumonitis requires a combination of clinical suspicion, imaging, and exclusion of other causes.

1. Clinical assessment

• Detailed timeline linking symptom onset to Y‑90 therapy.
• Physical exam: inspiratory crackles, wheezes, or reduced breath sounds.

2. Imaging studies

• Chest X‑ray – may show diffuse or patchy infiltrates, often peripheral.
• High‑resolution CT (HRCT) – preferred; typical findings include ground‑glass opacities, reticulation, and consolidation confined to the radiation field.

3. Pulmonary function tests (PFTs)

• Reduced diffusing capacity for carbon monoxide (DLCO) is common.
• Obstructive or restrictive patterns may develop in severe cases.

4. Laboratory work

• Complete blood count (CBC) to rule out infection.
• C‑reactive protein (CRP) and erythrocyte sedimentation rate (ESR) – mildly elevated in inflammation.

5. Exclusion of other etiologies

• Microbiologic cultures (sputum, blood) if fever or purulent sputum.
• Echocardiogram to exclude cardiac‑related pulmonary edema.
• Bronchoscopy with broncho‑alveolar lavage (BAL) only when infection cannot be ruled out.

Diagnostic criteria (adapted from Common Terminology Criteria for Adverse Events, CTCAE v5.0)

• Grade 1: Asymptomatic; radiographic findings only.
• Grade 2: Symptomatic; medical intervention indicated (e.g., corticosteroids).
• Grade 3: Severe symptoms; oxygen needed.
• Grade 4: Life‑threatening respiratory failure.

Treatment Options

Management centers on reducing inflammation, supporting respiratory function, and preventing progression.

1. Corticosteroids (first‑line)

• Prednisone 1 mg/kg/day (≈60 mg) for 4‑6 weeks, then taper over 4‑6 weeks based on symptom resolution.
• For severe cases (grade ≥3), intravenous methylprednisolone 1‑2 mg/kg/day may be initiated, then switched to oral taper.
• Evidence from small case series shows response rates of 70‑85% when steroids start within 2 weeks of symptom onset.<sup>3</sup>

2. Oxygen therapy

• Supplemental low‑flow oxygen (nasal cannula) to maintain SpO₂ ≥ 92%.
• High‑flow nasal cannula or non‑invasive ventilation (BiPAP) for moderate hypoxia.
• Mechanical ventilation in life‑threatening respiratory failure (grade 4).

3. Adjunctive immunomodulators (selected cases)

• Azithromycin 250 mg three times weekly for 3 months – anti‑inflammatory effect, limited data.
• Mycophenolate mofetil or cyclophosphamide – considered for steroid‑refractory disease, only in specialist centers.

4. Antimicrobial coverage

If infection cannot be excluded, start broad‑spectrum antibiotics (e.g., ceftriaxone + azithromycin) while awaiting culture results. Discontinue if cultures are negative and imaging supports radiation pneumonitis.

5. Lifestyle & supportive measures

• Smoking cessation – the most important modifiable factor.
• Pulmonary rehabilitation: breathing exercises, graded activity program.
• Vaccinations: annual influenza and pneumococcal vaccines to reduce superimposed infections.

Living with Yttrium‑90 Microsphere Radiation Pneumonitis

While most patients improve with treatment, ongoing self‑care is essential.

Daily management tips

• Monitor symptoms – keep a log of cough, shortness of breath, temperature, and activity tolerance.
• Medication adherence – take steroids exactly as prescribed; use a pill organizer.
• Energy conservation – break tasks into short intervals, sit while performing chores.
• Breathing techniques – pursed‑lip breathing and diaphragmatic breathing reduce dyspnea.
• Hydration – adequate fluid intake helps keep secretions thin.
• Follow‑up appointments – pulmonary function tests and imaging at 3‑month intervals until stable.

Psychosocial aspects

• Connect with patient support groups for liver cancer and radiation pneumonitis.
• Consider counseling if anxiety or depression develops due to chronic illness.

Prevention

Because radiation pneumonitis is iatrogenic, prevention focuses on meticulous procedural planning and patient selection.

1. Pre‑procedural lung‑shunt assessment – Perform a Tc‑99m MAA scan; if LSF is >10‑15%, reduce planned Y‑90 activity or consider alternative therapy.
2. Adhere to manufacturer dose limits – Do not exceed the recommended lung dose (30 Gy for a single session; 50 Gy cumulative for staged treatments).
3. Selective catheter placement – Use super‑selective hepatic artery catheterization to avoid non‑target embolization.
4. Use of protective embolic agents – Temporary embolic material can reduce microsphere reflux.
5. Optimize patient condition – Treat COPD, asthma, or interstitial lung disease before SIRT.
6. Post‑procedure monitoring – Schedule a chest CT at 4–6 weeks after high‑dose procedures to detect early changes.

Complications

If radiation pneumonitis is not identified or treated promptly, several serious complications may arise:

• Progressive fibrosis – Chronic scarring leading to irreversible restrictive lung disease.
• Acute respiratory distress syndrome (ARDS) – Rapidly worsening hypoxemia, often requiring intensive care.
• Secondary infections – Steroid therapy combined with impaired lung defenses predisposes to bacterial or fungal pneumonia.
• Pulmonary hypertension – Long‑term vascular remodeling from fibrosis.
• Reduced tolerance for future cancer therapies – Limits ability to receive additional systemic or locoregional treatments.

When to Seek Emergency Care

---

<sup>1</sup> Mayo Clinic. “Yttrium‑90 Radioembolization.” Updated 2023. https://www.mayoclinic.org

<sup>2</sup> Bourhis J, et al. “Lung dose assessment after Y‑90 radioembolization.” J Vasc Interv Radiol. 2021;32(4):567‑575.

<sup>3</sup> Kawamoto S, et al. “Management of radiation pneumonitis following Y‑90 radioembolization: a multicenter experience.” Radiology. 2022;304(2):321‑330.

CDC. “Radiation Safety and Prevention.” 2024. https://www.cdc.gov

NIH National Cancer Institute. “Radioembolization (Y‑90) for Liver Cancer.” 2023. https://www.cancer.gov

```